Molecular targets in ovarian cancer
Agarwal R., Blagden S.
Despite advances in the management of epithelial ovarian cancer, it remains the most lethal of gynecological malignancies in the UK. Ovarian cancer is a complex disease, both in its molecular and clinical behavior. Targeted therapies have yet to show an improvement in five-year survival when added to standard cytotoxic chemotherapy. However, a recent redefinition of the disease along with the discovery of unique molecular targets has provided new avenues for therapeutic development. In this review, we summarize the main targeted therapies that are currently in clinical development alongside those that are due to enter the clinical arena.